2 Hot Stock Updates: First Horizon National Corporation (NYSE:FHN), ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC)

First Horizon National Corporation (NYSE:FHN)

The shares of First Horizon National Corporation (NYSE:FHN) started off the last trading session with the price of $19.9 while closing the day with the price of $19.89. The shares of First Horizon National Corporation (NYSE:FHN) Rise 0.51% with the Loss of -0.01 points.

The shares of First Horizon National Corporation (NYSE:FHN) traded with the day volume of 2.59 Million shares whereas its average trading volume is 3.46 Million.

While analyzing the past performance of the stock we can see that the shares of First Horizon National Corporation (NYSE:FHN) Loss -0.55% in the last week while rising 4.35% in the last month. Past quarter performance shows the green light with 0.2%. The semi-annual and annual performance shows 13.01% and 4.46% respectively.

Some critical values of the shares of First Horizon National Corporation (NYSE:FHN) to be discussed here are: the beta which shows the value at 1.01 while Average True Range of First Horizon National Corporation (NYSE:FHN) demonstrate the value at 0.5. The weekly and monthly volatility of the shares of First Horizon National Corporation (NYSE:FHN) are indicated at 1.88% and 2.46%. Also to discuss here is the Relative Strength Index or RSI which is depicted at 52.02.

While studying the financial position of the shares of First Horizon National Corporation (NYSE:FHN), we can see that the Market capitalization of the company is at 6.38 Billion. The shares outstanding for the company is 320.9 Million and the shares float stands at 320.9 Million. The income of the company stand at 241.3 Million while the sales stand at 989.9 Million.

Here are some critical ratios for a financial perspective: Earnings Per Share or EPS of the company stand at 1.01, Price to Earnings or P/E is at 19.75, Price to Sales P/S show the value of 6.45, the Return on Asset ROA stood at 0.005 and the Return on Equity ROE depicted at 0.056 while Return on Investment ROI is at 0.147.


ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC)

ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) started its previous trading session at $0.28 and closed at $0.25 showing a Fell of -9.35 Percent.

The Company traded with an average Volume of 1.83 Million whereas, its Day Volume stood at 2.59 Million.

Looking at the performance of the stock, ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) Loss -18.2% in the last week in its shares price and -2.73% in the last month. Quarterly performance shows a green of 11.16 Percent while Semi-Annual and Annual performances shows a -18.39 and -90.08 percent respectively.

Beta for ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) stands at 0.59 while the ATR (average true range) is at 0.03. The Stock’s Weekly and Monthly Volatility is 11.78% and 10.76% respectively showing a RSI value of 42.39.

While studying the financial position of the shares of ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC), we can see that the Market capitalization of the company is at 5.78 Million. The shares outstanding for the company is 22.84 Million and the shares float stands at 22.84 Million.

The Company generated an income of -22400000 and the sales of 0 in the Trailing Twelve Months period.

While analyzing the stock from technical aspects, Diluted Earnings per share stands at $-3.05 a share. P/E (price to earnings) and P/S (price to sales) values are 0 and 0 respectively.

The Return on Assets stands at -2.245, ROE shows a value of 0 and ROI for ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) is 0 as of Trailing Twelve Months period.

View all contributions by

Eldred Matthew covers Healthcare Sector Company recent Press Releases news updates. He has three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

    Leave a Comment